Fourth, while we included some therapies that had off‐label use for metastatic NSCLC, such as pyrotinib for HER2‐mutated NSCLC, we were unable to include all potential therapies that are used off‐label for NSCLC with actionable mutations. Here, ERBB2 is linked to non-small cell lung carcinoma.